Cargando…
On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies
Chimeric Antigen Receptor T cells, or CAR-Ts, are a novel class of gene and cell ‘one-shot’ therapies based upon collecting, reprogramming, and using patients’ own immune cells to treat their cancer. The article discusses the status, prospects, and some relevant legal issues of this frontier of pers...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507023/ https://www.ncbi.nlm.nih.gov/pubmed/36168389 http://dx.doi.org/10.1093/jlb/lsac027 |